Abstract:Abstract Abstract 1949 Introduction Transmission of hepatitis B virus (HBV) may occur (de novo HBV infection) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) from HBsAg-positive donors into HBsAg-negative recipients. Increased HBV associated complications will cause high morbidity and mortality post-transplantation in such patients. China is an endemic area for HBV infection. The exclusion of HBsAg positive donors will greatly limit the application of HSCT. There are few published data on allo-HSCT from HBsAg-positive donors when no other alternatives can be available. Recently great advances in anti-HBV therapy and prophylaxis have been achieved. The efficacy of allo-HSCT combined with anti-HBV prophylaxis in such patients remains unknown. In the current study, we performed a retrospective analysis of the virologic and clinical outcomes of allo-HSCT from HBsAg-positive donors into HBsAg-negative recipients under active prophylactic anti-HBV therapy. Methods From 2005 to 2010, a total of 10 HBsAg-negative recipients undergoing allo-HSCT from HBsAg-positive donors in our single center were included as an observation group. We performed a matched case-controlled analysis, in which each HBsAg-positive transplantation was paired with 3 control subjects selected from among all seronegative transplantation defining as a matched control group (30 patients). Patients were matched on age, underlying disease, disease stage, conditioning regimen and donor type. All the enrolled patients underwent HLA-matched related (20% each group) and HLA-mismatched related (haploidentical, 80% each group) transplantation. For haploidentical HSCT, conditioning regimen consisted of Ara-C, busulfan (Bu), cyclophosphamide (Cy), Me-CCNU and ATG. For HLA-matched related HSCT, the conditioning regimen consisted of Bu and Cy. GVHD prophylaxis consisted of cyclosporine A, mycophenolate mofetil and short-term methotrexate. Anti-HBV therapy consisted of lamivudine or entecavir for HBsAg positive donors. Marrow harvest and HSCT were performed until donor's serum HBV-DNA became undetectable. Hepatitis B immunoglobulin (HBIg) of 400 IU were administered to the recipients within 24 hours, 1 month and 2 months after stem cell infusion, respectively. HBsAb titers were detected once a month. If the titer was lower than 200IU/L, HBIg was injected rapidly. All the patients were followed-up weekly and HBV serology was detected once a month. Reults After transplantation, 1 and 0 patient developed HBV-related hepatitis in observation group and matched control group (P>0.05). The HBV-related hepatitis patient became positive for HBsAg 1 year post-transplantation with serum HBsAb loss. Interestingly, this patient became negative for HBsAg and positive for HBsAb after donor lymphocyte infusion due to the primary disease relapse. To date, none of the enrolled recipients in our study became positive for HBsAg. Veno-occlusive disease (VOD) is another kind of hepatic complication. One and 0 patient developed VOD in observation group and matched control group respectively (p>0.05). The presence of HBcAb in the absence of HBsAg in serum indicates past exposure to HBV. Despite the presumed resolution of the HBV infection in these patients, a minute amount of HBV DNA remains in the liver. So we analyzed HBcAb and HBsAb levels in the serum in both groups 1 year post-transplantation. Nine (90.0%) and 6 (20.0%) patients became positive for both HBcAb and HBsAb in observation group and matched control group respectively (p<0.01), suggesting possible occult HBV infection in recipients transplanted from HBsAg-positive donors. We also compared clinical outcomes between 2 groups. The incidence of aGVHD was 40.0% in obervation group and 30.0% in matched control group (p>0.05). The 1 year overall survival (OS) were 60.0% and 63.3% in observation group and matched control group respectively (p>0.05). The 1 year non-relapse mortality (NRM) were 10.0% and 13.3% in observation group and matched control group respectively (p>0.05). Conclusions Our data support that allo-HSCT from HBsAg-positive donors into HBsAg-negative recipients is a safety and practicable regimen under active prophylactic anti-HBV therapy, but these recipients are possibly complicated with occult HBV infection. A long-term prospective follow-up study on such patients is imperative currently. Disclosures: No relevant conflicts of interest to declare.

[Immunoregulation of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Hepatitis B-related End-Stage Liver Disease].

[Effects of Autologous Peripheral Stem Cell Transplantation on Acoustic Radiation Force Impulse in Patients with HBV-related Decompensated Cirrhosis].

Immune regulatory effect of bone marrow mesenchymal stem cells of patient with hepatitis B virus related decompensated cirrhosis

Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis

Allogeneic Hematopoietic Stem Cell Transplantation from HBsAg-Positive Donors into HBsAg-Negative Recipients: A Safety and Practicable Regimen under Active Prophylactic Anti-HBV Therapy

Controlled Trials in Hepatitis B Virus-Related Decompensate Liver Cirrhosis: Peripheral Blood Monocyte Transplant Versus Granulocyte-Colony-Stimulating Factor Mobilization Therapy

Effect of regulatory T cells and adherent cells on the expansion of HBcAg-specific CD8+ T cells in patients with chronic hepatitis B virus infection

Effects of Regulatory T Cells on Anti-Viral Immune Responses Impaired by Chronic Hepatitis B

Clinical Study of Liver Injury Associated with Autologous Hematopoietic Stem Cell Transplantation

Therapeutic Potential of Peripheral Blood Stem Cell Transplantation in One Cirrhotic Patient Caused by Hbv Combined with Hcv

Short-term effect of allogeneic mesenchymal stem cells in patients with end stage of liver diseases due to HBV and effects on the balance of Th1/Th2 axis

A Clinic Study on Long-term Efficacy and Safety of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Decompensated Hepatitis B Cirrhosis

Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients with Cirrhosis

Bone Marrow-Derived Stem Cells Ameliorate Hepatic Fibrosis by Down-Regulating Interleukin-17

Recovery of Circulating CD56dim NK Cells and the Balance of Th17/Treg after Nucleoside Analog Therapy in Patients with Chronic Hepatitis B and Low Levels of HBsAg

Effect and Clinical Significance of Glucocorticoid on CD4+CD25+ Regulatory T Cells in Patients with Hepatitis B Virus-Related Pre-Liver Failure

Kinetics of Phytohemaglutinin-Induced IFN-γ and TNF-α Expression in Peripheral Blood Mononuclear Cells from Patients with Chronic Hepatitis B after Liver Transplantation

[Effects of Hepatovirus B Infection on the Hematopoietic Stem Cell Collection and Implantment in Lymphoma Patients Received Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation].

Regulatory T Cells And Il-17(+) T Helper Cells Enhanced In Patients With Chronic Hepatitis B Virus Infection

The efficacy and long-term safety of autologous bone marrow stem cells transplantation in patients with hepatitis B virus-associated decompensated liver cirrhosis

Effects of the Treg/Th17 Cell Balance and Their Associated Cytokines in Patients with Hepatitis B Infection